Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Purchased by Man Group plc

Man Group plc lifted its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 37.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 214,113 shares of the company's stock after purchasing an additional 58,642 shares during the quarter. Man Group plc owned 0.38% of Harmony Biosciences worth $7,368,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. KBC Group NV raised its position in Harmony Biosciences by 79.9% in the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock valued at $63,000 after purchasing an additional 819 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in shares of Harmony Biosciences by 28.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,328 shares of the company's stock valued at $80,000 after buying an additional 519 shares during the period. Summit Investment Advisors Inc. grew its position in Harmony Biosciences by 34.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,987 shares of the company's stock valued at $137,000 after acquiring an additional 1,029 shares in the last quarter. Avanza Fonder AB bought a new position in Harmony Biosciences during the 4th quarter worth approximately $145,000. Finally, CIBC Private Wealth Group LLC raised its position in shares of Harmony Biosciences by 66.4% during the 4th quarter. CIBC Private Wealth Group LLC now owns 4,214 shares of the company's stock worth $146,000 after purchasing an additional 1,681 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a research note on Tuesday, February 11th. They set a "buy" rating and a $55.00 price objective for the company. Mizuho lifted their price objective on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research note on Thursday, May 15th. UBS Group decreased their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating on the stock in a report on Monday, April 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a research report on Tuesday, April 8th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $49.00 target price on shares of Harmony Biosciences in a report on Tuesday, May 6th. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Harmony Biosciences currently has an average rating of "Buy" and an average price target of $52.78.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY traded up $0.04 during midday trading on Friday, reaching $34.17. 392,819 shares of the stock were exchanged, compared to its average volume of 602,079. Harmony Biosciences Holdings, Inc. has a twelve month low of $26.47 and a twelve month high of $41.61. The company has a quick ratio of 3.20, a current ratio of 3.24 and a debt-to-equity ratio of 0.28. The firm has a 50-day simple moving average of $31.58 and a two-hundred day simple moving average of $34.01. The firm has a market cap of $1.96 billion, a price-to-earnings ratio of 16.19, a PEG ratio of 0.47 and a beta of 0.82.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.78 EPS for the quarter, beating analysts' consensus estimates of $0.59 by $0.19. The company had revenue of $184.73 million during the quarter, compared to the consensus estimate of $184.26 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. Harmony Biosciences's quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the company earned $0.67 earnings per share. As a group, analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current fiscal year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.